Back to results
US 6,387,695 B1Granted
DNA pharmaceutical formulations comprising citrate or triethanolamine and combinations thereof
AssigneeMerck & Co., Inc.
InventorsRobert K. Evans, David B. Volkin, Mark W. Bruner, Zheng Xu
Life of this patent
Estimating the term…
Abstract
The present invention relates to nucleic acid formulations of pharmaceutical products which comprise citrate and/or triethanolamine in concentrations which enhance stability of the nucleic acid. These formulations are suited for situations where prolonged storage occurs during the distribution and/or storage period prior to use.
Claims20
A nucleic acid formulation comprising:
- a) a nucleic acid molecule;
- b) an amount of a pharmaceutically acceptable buffer to adjust the pH from about 7.0 to about 9.5;
- c) a salt at concentration from about 100 mM to about 300 mM;
- and,
- d) citrate or a pharmaceutically acceptable salt thereof at a concentration less than 15 mM.
2 more elements
A DNA plasmid formulation comprising:
- a) a DNA plasmid molecule;
- b) an amount of a pharmaceutically acceptable buffer to adjust the pH from about 7.0 to about 9.5;
- c) a salt at concentration of up to about 300 mM;
- and
- d) triethanolamine or a pharmaceutically acceptable salt thereof at a concentration of about 0.1 mM to about 10 mM,
- wherein the DNA plasmid formulation is free of carrier molecules.
3 more elements
The nucleic acid formulation comprising:
- a) a nucleic acid molecule;
- b) an amount of a pharmaceutically acceptable buffer to adjust the pH from about 7.0 to about 9.5;
- c) a salt at a concentration of up to about 300 mM;
- d) citrate or a pharmaceutically acceptable salt;
- and,
- e) triethanolamine or a pharmaceutically acceptable salt thereof,
- wherein the nucleic acid formulation is free of carrier molecules.
4 more elements
Dependencies are inferred from the claim text.